

NOVADEL PHARMA INC  
Form 8-K  
March 23, 2007

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported) March 23, 2007**

**NOVADEL PHARMA INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-32177**  
(Commission File No.)

**22-2407152**  
(I.R.S. Employer  
Identification No.)

**25 Minneakoning Road**  
**Flemington, New Jersey 08822**

(Address of principal executive offices) (Zip Code)

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

(908) 782-3431

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On March 23, 2007 NovaDel Pharma Inc., a Delaware corporation ( NovaDel ), issued a press release announcing that its licensee for ondansetron oral spray, Hana Biosciences Inc. ( Hana Biosciences ), has notified NovaDel that it intends to re-direct the development plan for Zensana<sup>TM</sup> by using NovaDel's patent-protected European formulation of the product. Zensana<sup>TM</sup> is an oral spray formulation of ondansetron targeted for the prevention of chemotherapy-, radiotherapy-induced and post-operative nausea and vomiting. Hana Biosciences announced its plan to withdraw, without prejudice, its pending New Drug Application ( NDA ) for Zensana<sup>TM</sup> with the Food and Drug Administration ( FDA ). Subject to the successful scale-up and manufacturing test of NovaDel's European formulation of ondansetron, Hana expects to conduct the appropriate clinical trials and re-file the NDA for Zensana<sup>TM</sup> in 2008. The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press release dated March 23, 2007, titled NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana<sup>TM</sup>.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Michael E. Spicer  
Name: Michael E. Spicer  
Title: Chief Financial Officer and Corporate Secretary

Date: March 23, 2007